A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC
Status:
Completed
Trial end date:
2021-04-27
Target enrollment:
Participant gender:
Summary
This is an open-label, Single-arm, Phase I clinical study to evaluate the pharmacokinetics,
tolerability and safety of margetuximab plus chemotherapy in Chinese patients with advanced
HER2+ breast cancer who have received standard anti-HER2 directed therapy in the metastatic
setting (mandatory including trastuzumab).
The primary endpoint of this study is PK parameters of margetuximab.